CVS Caremark Study Finds $100 Mil. Opportunity For Medicaid In Generic Switching Without Patient Consent
This article was originally published in The Pink Sheet Daily
Executive Summary
With big patent expirations approaching in 2011 for Lipitor, Zyprexa and Plavix, CVS Caremark is promoting aggressive generic substitution policies by state Medicaid programs as a way to save more than $100 million.
You may also be interested in...
Pharmacy-Related Waste Exceeded $403 Billion In 2010 – Express Scripts
Pharmacy benefits manager Express Scripts reported that in 2010, $403 billion in pharmacy-related waste could have been avoided across three areas – the sales channel, generic utilization and nonadherence to medications.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.